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INTRODUCTION
A combination product of olanzapine and samidorphan (OLZ/SAM) is in development for the treatment of schizophrenia and bipolar disorder. Approved in the United States (US) in 1996, olanzapine (Zyprexa ® ) 1 is widely regarded as an efficacious treatment option for schizophrenia [2] [3] [4] [5] and bipolar disorder, 6, 7 but its clinical utility is severely limited by the risk of weight gain and metabolic dysfunction associated with its use. [5] [6] [7] Treatment with OLZ/SAM resulted in similar antipsychotic efficacy to olanzapine in a 3month phase 2 study in patients with schizophrenia. 8 In addition, there was reduced weight gain with OLZ/SAM compared with olanzapine in healthy volunteers and patients with schizophrenia. 8, 9 Samidorphan is a new molecular entity opioid receptor antagonist and has a unique pharmacokinetic, binding, and activity profile compared with naltrexone. 10 In vitro, samidorphan exhibits partial agonist activity at κ-and δ-opioid receptors while having high-affinity antagonist effects at µ-opioid receptors, an effect that is recapitulated in humans. [11] [12] [13] Evidence for the involvement of the opioid pathway in regulating some aspects of weight gain and metabolism comes from animal models and human studies where opioid receptor signaling has been disrupted genetically and pharmacologically, respectively. 14 In clinical pharmacokinetic, safety, and efficacy studies, OLZ/SAM was generally well tolerated, with a safety profile similar to olanzapine alone. 8, 9, 15, 16 Olanzapine has been associated with a low risk for QT prolongation, 17 reported. 18 However, a thorough QT/QTc (tQT) study was not conducted with olanzapine. Therefore, in line with the recommendations made by the International Council for Harmonisation guidelines on adequate characterization of electrocardiogram (ECG) effects for combination drug products, 19 a tQT study was conducted to evaluate the effect of the combination OLZ/SAM, at supratherapeutic doses and concentrations of both olanzapine and samidorphan, on cardiac repolarization, an effect that can be measured as prolongation of QT interval. Because higher doses of olanzapine monotherapy (ie, ≥20 mg) are not tolerated in healthy subjects, this study was conducted in patients with a diagnosis of schizophrenia in order to achieve supratherapeutic dose and exposure levels required for a tQT study.
METHODS
This was a phase 1, randomized, double-blind, placebo-and positive (moxifloxacin)controlled, parallel-group, multiple-dose study in patients with schizophrenia. This study used the positive control, moxifloxacin, to ensure that small changes in the QT interval could be detected, in accordance with current regulatory guidance. 20 The study was Edition 21 (DSM-5)-confirmed diagnosis of schizophrenia that was clinically stable based on the investigator's clinical judgment, and at a minimum defined as having no exacerbation of psychotic symptoms or psychiatric hospitalization for ≥3 months before screening and a Clinical Global Impression-Severity (CGI-S) score ≤3 at screening. In addition, eligible patients were required to have received continuous treatment with an antipsychotic for ≥6 months prior to washout. Screening supine blood pressure was required to be between 90/40 and 140/90 mm Hg. Lastly, patients could have no clinically significant history or presence of ECG findings at screening and on day −2. Patients met eligibility criteria if heart rate (HR) was 45-100 beats per minute (bpm), corrected QT interval using Fridericia's formula (QTcF) 22, 23 was ≤450 msec, QRS interval was ≤110 msec (confirmed by manual over-read if >110 msec), and PR interval was ≤220 msec.
Patients were excluded for any of the following: presence of a clinically significant risk for suicide or causing harm to others based on the Columbia-Suicide Severity Rating Scale (C-SSRS); a known or suspected intolerance, allergy, or hypersensitivity to olanzapine, opioid antagonists, moxifloxacin, or antimicrobials of the quinolone class; a DSM-5 diagnosis of substance use disorder within the 3 months prior to screening J o u r n a l P r e -p r o o f Journal Pre-proof A109 tQT 9 (except tobacco-related disorder; cigarettes ≤20 per day were permitted); a positive drug screen for alcohol, amphetamines, barbiturates, cocaine, or opioids at screening/clinic admission visit; significant extrapyramidal symptoms in the 3 months prior to screening; treatment with a depot antipsychotic in the last 6 months (or the 3month formulation of paliperidone palmitate in the last 12 months); or clozapine use within 6 months prior to screening. Additionally, a history of, or presence of, clinically significant hypokalemia, the presence of risk factors for torsades de pointes (eg, heart failure, cardiomyopathy, family history of long QT syndrome, or hypertension, angina, bradycardia, or severe arterial circulatory disorders), sick sinus syndrome, second-or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or conduction abnormalities was exclusionary.
Patients were not eligible for participation in the study if they had diabetes, hemoglobin A1c levels ≥6.5%, or dyslipidemia (total fasting cholesterol >280 mg/dL or fasting triglycerides >500 mg/dL) at screening. Finally, patients who had taken opioid agonists (eg, codeine, oxycodone, tramadol, or morphine) within the 2 weeks prior to inpatient admission, or in whom the need for opioid medication during the study was anticipated (eg, planned surgery), were not eligible for study entry. During the study, the use of caffeine-or xanthine-containing products was prohibited 8 h prior to and during ECG collection, and alcohol was not permitted 72 h prior to and during clinic admission. Concomitant benzodiazepines for the treatment of extrapyramidal symptoms or insomnia, agitation, or anxiety were allowed, as well as J o u r n a l P r e -p r o o f Journal Pre-proof mood stabilizers and antidepressants, given the individual was maintained at a stable dose for ≥3 months prior to study entry. Other prohibited medications during the study included monoamine oxidase inhibitors; medications with drug-interaction potential with olanzapine 1 or moxifloxacin; medications contraindicated to moxifloxacin; medications with documented effects of increases in QT interval on the US package insert (except study drug); strong inhibitors or inducers of cytochrome P450 3A within 30 days of randomization; and opioid agonists (within 14 days prior to screening) or antagonists (within 60 days prior to screening). Upon completion of the inpatient treatment period, patients restarted standard-of-care treatment. 
Cardiodynamic Assessments

Statistical Analyses
The primary endpoint was the change from baseline in QTcF (ΔQTcF). Secondary 
RESULTS
Participant Disposition, Demographics, and Baseline Characteristics
A total of 100 patients were randomized and received study drugs, and 84 completed the study. Overall, 16 patients discontinued from the study (10 from group 1, and 3 each from groups 2A and 2B); the most common reasons for discontinuation from any group were withdrawal by patients (n=8) and AEs (n=4). Among all patients, the mean age was 43.9 years, 76% were male, and the mean CGI-S score was 2.9 at baseline. Additional baseline characteristics, including mean ECG characteristics, are presented in Table 1 .
Effect on HR
Mean ΔHR values were generally small and followed a similar pattern with OLZ/SAM Table 3 ). The median t max was observed between 4 and 5 h for olanzapine and between 1 and 2 h for samidorphan across all dose levels.
Concentration-QTc Analysis
Based on primary analysis using C-QTc modeling, a clinically concerning QTc effect (ie, ∆ΔQTcF ≥10 msec) can be excluded across the OLZ/SAM dose range tested (10/10 to 30/30 mg) and up to olanzapine and samidorphan concentrations of approximately 110 and 160 ng/mL, respectively (Figure 4A and 4B Assay sensitivity was demonstrated by the C-QTc relationship of moxifloxacin ( Figure 5) , in which the slope was statistically significant (0.01 msec per ng/mL; 90% CI: 0.00, 0.01; P<0.01), and the lower bound of the 90% CI at the observed geometric mean C max of moxifloxacin (1806 ng/mL) was >5 msec (predicted ΔΔQTcF [90% CI]: 9.5 [5.68, 13 .33] msec).
Additional ECG Parameters: Effect on PR and QRS Interval and T-Wave
Morphology
Mean ΔPR values were generally small and followed similar patterns for OLZ/SAM 
DISCUSSION
In this tQTc study, multiple once-daily oral administration of OLZ/SAM over the dose range from therapeutic (10/10 mg) 8 (geometric mean C max of 59.4 and 43.9 ng/mL, respectively). 16 Given that the current study was conducted in the target patient population for OLZ/SAM without controlling for intrinsic (eg, age, sex, race) and extrinsic (eg, smoking) factors that are known to affect pharmacokinetics of olanzapine [27] [28] [29] but not samidorphan, 16 
TABLES
